Hormonal & sexual functionNasal spray

PT-141

Also known as: Bremelanotide · Vyleesi

PT-141 (bremelanotide) is a peptide that acts on melanocortin receptors in the nervous system, with an approved use for a specific sexual-health condition and study for sexual-function pathways.

Physician-reviewedDr. Bushra Mir, Medical Director · DHA-licensedReviewed 10 July 2026

The molecule, up close

Class: Melanocortin-receptor agonist peptide
Origin: Developed from melanocortin-system research
Chemistry: Cyclic heptapeptide
Typical format: Injectable (approved); nasal (studied)
Regulatory status: Approved for a specific indication in some markets

This page is educational information, not medical advice or an offer of treatment. Peptides used clinically are prescription medicines; whether any is appropriate for you is a decision a physician makes after a diagnostic assessment.

What it is

PT-141, known medically as bremelanotide, is one of the few compounds here with a formal regulatory approval: in some markets it's approved (as Vyleesi) for a specific sexual-health condition in certain women. It works quite differently from the better-known erectile-dysfunction medicines.

Because it has an approved indication, more is known about it than about most research peptides — though that approval is narrow and specific, which is important context.

What it's studied for

It's studied for sexual-desire and arousal pathways, and is approved in some markets specifically for hypoactive sexual desire disorder in certain premenopausal women. Other uses are off-label.

The approved use is narrow and defined; broader use isn't established and is a medical decision.

The science

Unlike medicines that act on blood flow, PT-141 works centrally on melanocortin receptors in the nervous system that are involved in sexual response. This central mechanism is what distinguishes it.

That same receptor family is involved in other functions, which is relevant to its effects and side-effect profile.

Typical form

Nasal spray

Shown in the dispensing format most often used in research and clinical settings. Where any protocol is appropriate, the route, dose and schedule are a physician’s decision — not a fixed recipe.

Safety & considerations

PT-141 is a prescription medicine with defined indications, contraindications — including blood-pressure considerations — and monitoring. It should be used only under medical supervision.

Its central mechanism and effects on other systems mean a proper medical assessment is important before use.

Status & oversight

PT-141 is approved for a specific indication in some markets under the name bremelanotide; other uses are physician-directed.

Common questions

PT-141, in brief.

What is PT-141 (bremelanotide)?

It's a peptide that acts centrally on melanocortin receptors involved in sexual response. It's approved in some markets for a specific condition and studied more broadly for sexual-function pathways.

How is PT-141 different from ED medications?

Common erectile-dysfunction medicines act on blood flow; PT-141 acts centrally on the nervous system's sexual-response pathways. Both are prescription-only and require medical assessment.

Is PT-141 approved?

In some markets it's approved (as bremelanotide/Vyleesi) for a specific sexual-health condition in certain women. Other uses are off-label and physician-directed.

Peptides of this kind are prescription medicines. Whether any protocol is appropriate is decided the way the rest of the practice works — from data, after an assessment.

How our longevity assessment works Back to the peptide field guide

How this is written

Physician-reviewed and evidence-led. We describe what a compound is studied for and where the evidence stands — not what it will do for you — and we revise pages as the science changes. Reviewed by Dr. Bushra Mir, Medical Director · DHA-licensed.

References

Peer-reviewed references for this compound are added by the physician author before publication.